Meeting
2020 Genitourinary Cancers Symposium
Immune checkpoint inhibitors (ICI) in clear cell renal cell carcinoma (ccRCC) following high-dose interleukin-2 (IL-2).
Authors
Roy Elias
University of Texas Southwestern Medical Center, Dallas, TX
Roy Elias , Isaac Alexander Bowman , Hans J. Hammers , James Brugarolas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 635)
Abstract #
635
Poster Bd #
D21
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase Ib study of endogenous T cell therapy using SLC45A2-specific CD8 T cells for patients with metastatic uveal melanoma.
First Author: Suzanne Phillips
Poster
2023 ASCO Genitourinary Cancers Symposium
The usefulness of meflin expression in cancer-associated fibroblasts as a predictive marker for immune checkpoint inhibitor in clear cell renal cell carcinoma.
First Author: Takayuki Owaki
Poster
2022 ASCO Annual Meeting
Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations.
First Author: Kelly N. Fitzgerald
Poster
2022 ASCO Genitourinary Cancers Symposium
Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).
First Author: Sophie Laramee